Research programme: cancer therapy - Shire BioChemAlternative Names: cancer therapy research programme - Shire BioChem
Latest Information Update: 17 May 2004
At a glance
- Originator Shire BioChem
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 May 2004 Discontinued - Preclinical for Cancer in Canada (unspecified route)
- 30 Apr 2002 Preclinical trials in Cancer in Canada (unspecified route)